Monthly Archives: March 2021

March 25, 2021

Advanced Proteome Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

2021-09-09T12:54:06-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the first tranche of its non-brokered private placement (the “Private Placement”) raising gross proceeds of $633,655.00 by the issuance of 3,091,000 units at a price of $0.205 per unit.

Advanced Proteome Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement2021-09-09T12:54:06-04:00
March 11, 2021

Advanced Proteome Therapeutics Announces Increase of Non-Brokered Private Placement

2021-09-09T12:54:21-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that it has increased its previously announced private placement financing (see March 1st, 2021 news release) from up to 6,097,561 units of the Company (“units) to up to 7,317,073 Units at a price of $0.205 per unit for gross proceeds of up to $1,500,000. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.27 per share.

Advanced Proteome Therapeutics Announces Increase of Non-Brokered Private Placement2021-09-09T12:54:21-04:00
March 1, 2021

Advanced Proteome Therapeutics Announces a Non-Brokered Private Placement

2021-09-09T12:54:37-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) announces that, subject to the approval of the TSX Venture Exchange (the “Exchange”), it proposes to raise up to $1,250,000 through a non-brokered private placement of up to 6,097,561 units at a price of $0.205 per unit. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.27 per share.

Advanced Proteome Therapeutics Announces a Non-Brokered Private Placement2021-09-09T12:54:37-04:00
Go to Top